The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment

Completed

Conditions studied: HIV Positive, Opioid Dependence, Opioid Agonist Treatment, HIV Infections

In brief

HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses: 1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%. 2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.

Key facts

Study ID

NCT00857350

Run by

Yale University

People needed

60

Starts

2008-06-01

Expected to finish

2012-09-01

Last updated by the study team

2013-07-22

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV+
• Opioid dependent
• Receiving methadone or buprenorphine for at least one month

You may not qualify if…

• age < 18 years
• current dementia;
• inability to read or understand English
• inability to provide written informed consent

Where it is running

• Yale University Hospital — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.